Zhejiang Medicine
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997 and listed on the Shanghai Stock Exchange.
Last updated October 7, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market, and in October its shares were listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan. Its product center covers API & Intermediate, Human Nutrition, Animal Nutrition, FDF, and Aroma Ingredient. The company reports research strength including 563 domestic invention patents and 164 international invention patents.
History
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market, and in October its shares were listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan. According to the company's development history, in 2014 'Changhai Biological Company' was merged into 'Zhejiang Medicine Co., Ltd. Changhai Biological Company', and in 2018 the Changhai Biological industrial park began to take shape, with most of its first-phase projects being completed and put into production. In 2010, three new projects were added to the list of national new drug innovation projects, and the company's research and industrialization projects on the purification, transformation, and microencapsulation of high-purity marigold pigment (lutein) and zeaxanthin won the first Scientific and Technological Progress Prize hosted by the China Light Industry Federation. In April 2011, under the…
- 2020
In January, Zhejiang Medicine donates medicine and cash to fight the epidemic, including 2 million yuan worth of medicine and 1 million yuan in cash on January 26, and a second batch of 3.1 million yuan worth of Nemonoxacin Malate Capsules to Wuhan, Hubei Province on January 27.
- 2018
The Changhai Biological industrial park begins to take shape, with most of its first-phase projects completed and put into production; as of the end of 2018, the company has 960 million yuan in registered capital and total assets of 10 billion yuan.
- 2017
Zhejiang Medicine is re-identified as a High-tech Enterprise in November.
- 2014
'Changhai Biological Company' is merged into 'Zhejiang Medicine Co., Ltd. Changhai Biological Company'.
- 2012
Zhejiang Pharmaceutical Enterprise Research Institute is listed as a key enterprise research institute in December; the company ranks first in Zhejiang Province's top 100 technological innovation capabilities.
- 2011
In April, further developments occur under the company's new production base program.
- 2010
Three new projects are added to the list of national new drug innovation projects; the company's research and industrialization projects on high-purity marigold pigment (lutein) and zeaxanthin win the first Scientific and Technological Progress Prize hosted by the China Light Industry Federation.
- 2009
Xinchang Pharmaceutical's innovative drug research and development team is identified as one of the first batch of provincial key enterprise technology innovation teams.
- 2008
Zhejiang Medicine is recognized as a High-tech Enterprise in October.
- 2007
The projects 'Research, Internationalization and Industrialization of Compound Artemether' and 'Vancomycin Key Technology R&D and Industrialization' each win the second prize of the National Science and Technology Progress Award.
Products and positioning
API & Intermediate
Active pharmaceutical ingredients and intermediates, a core product line listed on the company's product center.
Human Nutrition
Human nutrition products, including anti-oxidation and free radical scavenging preparations aimed at reducing lipofuscin production in women's skin.
Animal Nutrition
Animal nutrition products, part of the company's product portfolio.
FDF (Finished Dosage Form)
Finished dosage form pharmaceutical products, including Nemonoxacin Malate Capsules.
Aroma Ingredient
Aroma ingredients, one of the company's product categories.
Nemonoxacin Malate Capsules
An antibiotic medicine donated by the company to Wuhan, Hubei Province in January 2020 to fight the epidemic.
Compound Artemether
An antimalarial product whose research, internationalization and industrialization project won the second prize of the National Science and Technology Progress Award in 2007.
Vancomycin
An antibiotic whose key technology R&D and industrialization project won the second prize of the National Science and Technology Progress Award in 2007.
Natural d-α-Vitamin E
A vitamin E product whose process technology innovation project won the second prize of the National Science and Technology Progress Award in 2001.
Lutein and Zeaxanthin
High-purity marigold pigment (lutein) and zeaxanthin products; their purification, transformation and microencapsulation research and industrialization project won the first Scientific and Technological Progress Prize hosted by the China Light Industry Federation.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/zhejiang-medicine-china · Editorial policy · How profiles are compiled